ReviewCancer research2012
Intratumor heterogeneity: evolution through space and time.
Review in Cancer research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 520 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
520 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Application advances of habitat imaging based on CT or PET/CT: a systematic review.La Radiologia medica · 2026Pooled it
- Integrated imaging and molecular analysis to decipher tumor microenvironment in the era of immunotherapy.Seminars in cancer biology · 2022Pooled it
- Long-Term Efficacy of Pembrolizumab and the Clinical Utility of ctDNA in Locally Advanced dMMR/MSI-H Solid Tumors.Nature communications · 2025Trial
- Monitoring the Outcomes of Systemic Chemotherapy Including Immune Checkpoint Inhibitor for HER2-Positive Metastatic Gastric Cancer by Liquid Biopsy.Yonsei medical journal · 2023Trial
- Sodium accumulation in breast cancer predicts malignancy and treatment response.British journal of cancer · 2022Trial
- Chromosomal instability in cancer: sources, consequences and new therapeutic opportunities.Signal transduction and targeted therapy · 2026Review
- Digital Twins for Targeted Therapy in Head and Neck Cancer: From Molecular Stratification to Resistance-Aware Combination Strategies.Current oncology (Toronto, Ont.) · 2026Review
- Molecular Residual Disease in Non-Small Cell Lung Cancer: Technology or Patient Outcomes?Journal of personalized medicine · 2026Review
- Ascites reprograms innate lymphoid immune cells in ovarian cancer by promoting ILC2 enrichment and dysfunctional NK-cell states.Journal for immunotherapy of cancer · 2026Article
- Take Five: harmonization in personalized cancer vaccines for cancer immunotherapy.Experimental & molecular medicine · 2026Review
- Precision Risk Stratification in Prostate Cancer: Unveiling MRI-Based Habitat-Driven Radiomics Model for Enhanced Treatment Guidance.Journal of imaging informatics in medicine · 2026Article
- Tumor evolution: signaling pathways, molecular mechanisms and therapeutic targets.Signal transduction and targeted therapy · 2026Review
- ViMST: vision transformer-based dual modality multi-task graph contrastive network for spatial transcriptomics microenvironments investigation.BMC biology · 2026Article
- Article
- Electrochemical liquid biopsy across cancer care pathway.The journal of liquid biopsy · 2026Review
- Tumor stage, squamous histology and male sex predict positive resection margins in non-small cell lung cancer patients undergoing anatomical resection-a retrospective study from a high-volume thoracic surgery unit.Journal of thoracic disease · 2026Article
- Ensemble Optimal Control for Managing Drug Resistance in Cancer Therapies.Bulletin of mathematical biology · 2026Article
- Immune Evasion in Prostate Cancer: Resolving the Cold Tumour Paradox via a Hybrid Discrete-Continuum Computational Framework.Biology · 2026Article
- Correlation Between Thyroid Nodule Size and Risk of Thyroid Cancer: A Retrospective Cohort Study at a Tertiary Care Center.Diagnostics (Basel, Switzerland) · 2026Article
- The Current Landscape of Metastatic Breast Cancer: A Pathology Guide on Emerging Biomarkers.Cancers · 2026Review
460 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Recent technologic advances have permitted higher resolution and more rapid analysis of individual cancer genomes at the single-nucleotide level. Such advances have shown bewildering intertumor heterogeneity with limited somatic alterations shared between tumors of the same histopathologic subtype. Exacerbating such complexity, increasing evidence of intratumor genetic heterogeneity (ITH) is emerging, both within individual tumor biopsies and spatially separated between biopsies of the same tumor. Sequential analysis of tumors has also revealed evidence that ITH temporally evolves during the disease course. ITH has implications for predictive or prognostic biomarker strategies, where the tumor subclone that may ultimately influence therapeutic outcome may evade detection because of its absence or presence at low frequency at diagnosis or because of its regional separation from the tumor biopsy site. In this review, the implications of "trunk and branch" tumor evolution for drug discovery approaches and emerging evidence that low-frequency somatic events may drive tumor growth through paracrine signaling fostering a tumor ecologic niche are discussed. The concept of an "actionable mutation" is considered within a model of clonal dominance and heterogeneous tumor cell dependencies. Evidence that cancer therapeutics may augment ITH and the need to track the tumor subclonal architecture through treatment are defined as key research areas. Finally, if combination therapeutic approaches to limit the consequences of ITH prove challenging, identification of drivers or suppressors of ITH may provide attractive therapeutic targets to limit tumor evolutionary rates and adaptation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.